

SARC Semiannual Meeting Agenda

Friday, June 4, 2021

9:00 am – 12:00 pm EDT

9:00	Chawla-Rosenfeld Developmental Therapeutics Symposium	
	Introduction	Jonathan Fletcher, MD (Harvard Medical School)
	Overview of Radiomics Accomplishments	Amber Simpson, PhD (Queens University, Ontario)
	Radiomics-based Patient inclusion model improves clinical trial performance	Robert Gillies, PhD (Moffitt Cancer Center)
	Future Directions and Opportunities	Benjamin Haibe-Kains, PhD (University of Toronto)
	Discussion/Q&A	Speakers & Co-Moderators: Amandine Crombe, MD (Institut Bergonié) William Tap, MD (Memorial Sloan Kettering Cancer Center)
10:30	SARC Clinical Trials: Open/Opening	
	Principal Investigators	
	Introductions: SARC Medical Officer	Scott Okuno, MD
	SARC024: Phase 2 oral regorafenib in patients with selected sarcoma subtypes	Robert Maki, MD, PhD Steven Attia, DO Leo Mascarenhas, MD Richard Riedel, MD Christopher Ryan, MD
	SARC031: Phase 2 MEK inhibitor selumetinib w/ dual mTOR kinase inhibitor sirolimus in MPNST	AeRang Kim, MD, PhD Brigitte Widemann, MD
	SARC032: Phase 2 Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Soft Tissue Sarcoma of the Extremity	David Kirsch, MD, PhD Brian Brigman, MD, PhD Yvonne Mowery, MD, PhD Richard Riedel, MD
	SARC037: Phase I Trabectedin in Ewing Sarcoma in Combination with Irinotecan and 18F-FLT Imaging	Patrick Grohar, MD, PhD
	SARC038: Phase 2 Regorafenib in Combination with Nivolumab in Osteosarcoma	Fariba Navid, MD Lara Davis, MD
	SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS	Mark Dickson, MD
	Q&A	Speakers & Medical Officer
11:00	Sarcoma Advocacy	
	FDA Patient Advocacy Engagement	Leslie Doros, MD (Medical Officer, U.S. Food and Drug Administration)
	Sarcoma Coalition	Lynne Hernandez (Desmoid Tumor Research Foundation)
	SARC Sarcoma Research Advocacy Council	Peter Fantozzi (Northwest Sarcoma Foundation)
11:30	SARC Strategic Opportunities	
	The Future of SARC	Chappie Conrad, MD (Chair, Board of Directors)
	Maximizing Impact: Strategies & Resources	Steven Young (President & CEO)
	Scientific Challenges & Opportunities	Jonathan Fletcher, MD
	Q&A	Speakers
12:00	Adjourn	